Abstract
This review focuses on the roles of flow cytometric immunophenotyping has in the differential diagnosis of plasma cell neoplasms and the post-therapy monitoring of minimal (measurable) residual disease. The need to integrate flow cytometry data with clinical, laboratory, radiographic, morphological, and molecular genetic findings is emphasized. The challenges of and strategies for evaluating plasma cells in the setting of targeted therapy are also highlighted. © 2019 International Clinical Cytometry Society.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.